News

FibroGen is already conducting multiple phase II clinical studies of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors that stimulate erythropoiesis for the treatment of anemia, including the company’s lead

These will be the first human trials to assess the effectiveness of a ‘prime-boost’ vaccine using GenVec’s adenovector technology as a potential therapy for patients infected with HIV.

Auriga is developing an oral, controlled-release corticosteroid formulation that targets inflammatory bowel disease lesions at different sites within the gastrointestinal (GI) tract. Under the terms of the development

Flurizan is the first in a new class of investigative drugs known as selective amyloid lowering agents, or SALAs. This mechanism is different from the currently marketed drugs

Protalix has developed and patented a unique plant cell culture platform and bioreactor system that provides an efficient, easily scaleable and cost-effective system for the expression of human

The companies plan to use Medarex’ UltiMAb Human Antibody Development system to generate antibodies to novel disease targets provided by GenPat77. This technology can be used to help

Neuren’s phase IIa clinical trial investigated the safety, tolerability and pharmacokinetics of a four-hour infusion of Glypromate in 33 cardiac surgery patients. Of these, 12 patients received 3mg/kg/hr,

This trial is designed to identify the dose or doses of methylnaltrexone to be taken forward into the phase III clinical studies that will evaluate the efficacy, safety

The UC Davis study, which was co-authored by an international team that included scientists from the University of Hong Kong and Johns Hopkins University, has been published in